Profile data is unavailable for this security.
About the company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2019
- Employees78.00
- LocationAlto Neuroscience Inc650 Castro Street, Suite 450MOUNTAIN VIEW 94041United StatesUSA
- Phone+1 (773) 255-5012
- Fax+1 (302) 655-5049
- Websitehttps://www.altoneuroscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adicet Bio Inc | 0.00 | -117.88m | 107.95m | 143.00 | -- | 0.5103 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Karyopharm Therapeutics Inc | 148.44m | -87.48m | 109.32m | 325.00 | -- | -- | -- | 0.7365 | -0.7906 | -0.7906 | 1.17 | -1.27 | 0.6462 | 1.58 | 4.26 | 456,744.60 | -38.08 | -53.02 | -52.09 | -65.85 | 95.85 | 97.18 | -58.93 | -125.15 | 2.93 | -5.25 | 2.53 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -9.57m | 109.93m | 21.00 | -- | 0.0279 | -- | -- | -1,597.14 | -1,597.14 | 0.00 | 217.30 | 0.00 | -- | -- | 0.00 | -97.17 | -132.00 | -117.34 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 110.70m | 4.00 | -- | 5.08 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Invivyd Inc | 2.26m | -203.84m | 115.26m | 94.00 | -- | 0.8195 | -- | 50.91 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Alto Neuroscience Inc | -100.00bn | -100.00bn | 115.65m | 78.00 | -- | 0.6431 | -- | -- | -- | -- | -- | 6.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | -31.02 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 117.37m | 36.00 | 110.28 | -- | 42.92 | 2.40 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 118.38m | 102.00 | -- | 1.67 | -- | 994.79 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
| Allakos Inc | 0.00 | -178.75m | 119.95m | 131.00 | -- | 1.66 | -- | -- | -2.03 | -2.03 | 0.00 | 0.8142 | 0.00 | -- | -- | 0.00 | -87.64 | -42.71 | -97.01 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Coya Therapeutics Inc | 9.55m | -10.10m | 120.46m | 8.00 | -- | 3.11 | -- | 12.61 | -0.7726 | -0.7726 | 0.7589 | 2.32 | 0.3512 | -- | -- | 1,194,290.00 | -37.13 | -- | -40.92 | -- | -- | -- | -105.71 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 121.14m | 25.00 | -- | 3.91 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 121.73m | 233.00 | -- | -- | -- | 325.47 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Century Therapeutics Inc | 2.69m | -129.89m | 122.44m | 152.00 | -- | 0.6222 | -- | 45.60 | -1.86 | -1.86 | 0.0372 | 2.31 | 0.0068 | -- | -- | 17,664.47 | -33.04 | -- | -34.83 | -- | -- | -- | -4,837.73 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -60.34m | 123.98m | 54.00 | -- | 1.88 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 123.99m | 112.00 | -- | -- | -- | 5.01 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Alto Neuroscience Inc's reporting currency: US Dollar USD
53.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alpha Wave Global LPas of 30 Jun 2024 | 3.71m | 13.75% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 2.33m | 8.65% |
| RA Capital Management LPas of 30 Jun 2024 | 2.09m | 7.74% |
| Point72 Asset Management LPas of 30 Jun 2024 | 1.72m | 6.37% |
| Alkeon Capital Management LLCas of 30 Jun 2024 | 934.90k | 3.47% |
| ExodusPoint Capital Management LPas of 30 Jun 2024 | 836.09k | 3.10% |
| Jennison Associates LLCas of 30 Sep 2024 | 832.29k | 3.09% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 637.60k | 2.37% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 625.04k | 2.32% |
| Vestal Point Capital LPas of 30 Jun 2024 | 620.00k | 2.30% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
